Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BAX - Baxter International Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$20.00
DETAILS
HIGH:
$27.00
LOW:
$15.00
MEDIAN:
$19.50
CONSENSUS:
$20.00
UPSIDE:
4.28%
Stock News
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting
Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and a change related to board size.
Baxter International Still Has A Path To Upside
In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.
Madison Small Cap Fund Q1 2026 Portfolio Activity
ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.
Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.
Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates
Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago.
Baxter beats quarterly expectations on strong demand for medical devices
Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit.
Is Baxter International (BAX) 53.0% Undervalued After Q1 2026 Earnings Beat? Adjusted EPS $0.36 vs $0.11 est; Revenue $2.70B vs $2.62B est -- GF Score 57/100
On April 30, 2026, Baxter International Inc (BAX) released its 8-K filing detailing first-quarter 2026 results. Sales from continuing operations were $2.7 billi
Baxter Reports First-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps nec.
Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again?
BAX heads into Q1 earnings with revenues and profit set to fall sharply as operational pressures, weak demand and product disruptions weigh on results.
Baxter International (NYSE:BAX) vs. GN Store Nord (OTCMKTS:GNNDY) Head-To-Head Analysis
Baxter International (NYSE: BAX - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Risk and Volatility Baxter International has
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents, at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo, taking place April 11-14, 2026 in New Orleans. New offerings include the AAT XR spine surgical table and the Dynam.
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of “Hold” from Brokerages
Shares of Baxter International Inc. (NYSE: BAX - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to
Reviewing Zynex (NASDAQ:ZYXI) and Baxter International (NYSE:BAX)
Baxter International (NYSE: BAX - Get Free Report) and Zynex (NASDAQ: ZYXI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 90.2% of Baxter International shares
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy
BAX introduces the IV Verify system to improve IV labeling accuracy, targeting medication safety gaps and boosting workflow efficiency in clinical settings.
Price Targets
Baxter price target raised to $27 from $25 at Barclays
$27.00
(was $17.21)
Barclays
Baxter price target lowered to $17 from $21 at Goldman Sachs
$17.00
(was $20.54)
Goldman Sachs
Baxter price target lowered to $19 from $21 at UBS
$19.00
(was $19.79)
Danielle Antalffy
·
UBS
Baxter price target lowered to $20 from $22 at Deutsche Bank
$20.00
(was $19.23)
Deutsche Bank
Baxter price target lowered to $25 from $30 at Barclays
$25.00
(was $18.71)
Barclays
Baxter price target lowered to $19 from $21 at Jefferies
$19.00
(was $18.71)
Jefferies
Baxter price target lowered to $20 from $22 at Stifel
$20.00
(was $18.71)
Stifel Nicolaus
Baxter price target lowered to $30 from $36 at Barclays
$30.00
(was $20.69)
Matt Miksic
·
Barclays
Baxter price target raised to $23 from $22 at Goldman Sachs
$23.00
(was $20.69)
Goldman Sachs
Baxter price target lowered to $23 from $24 at Evercore ISI
$23.00
(was $20.02)
Vijay Kumar
·
Evercore ISI
Baxter price target lowered to $15 from $19 at Morgan Stanley
$15.00
(was $19.08)
Patrick Wood
·
Morgan Stanley
Baxter price target lowered to $22 from $25 at Goldman Sachs
$22.00
(was $18.81)
David Roman
·
Goldman Sachs
Baxter price target lowered to $22 from $25 at Stifel
$22.00
(was $19.18)
Stifel Nicolaus
Barclays cuts Baxter target, says selloff 'significantly overdone'
$36.00
(was $22.44)
Barclays
Baxter price target lowered to $24 from $35 at UBS
$24.00
(was $22.44)
UBS
Baxter price target lowered to $42 from $45 at Evercore ISI
$42.00
(was $29.26)
Vijay Kumar
·
Evercore ISI
BofA Securities Reiterates Neutral Rating on Baxter International (BAX)
$45.00
(was $36.32)
Travis Steed
·
Bank of America Securities
Baxter International (BAX) PT Lowered to $42 at Jefferies
$42.00
(was $36.92)
Matthew Taylor
·
Jefferies
Baxter downgraded to Underweight from Equal Weight at Morgan Stanley
$30.00
(was $35.32)
Patrick Wood
·
Morgan Stanley
Goldman Sachs Reiterates Neutral Rating on Baxter International (BAX)
$36.00
(was $33.31)
David Roman
·
Goldman Sachs